Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

WMGI - Wright Medical Group NV


Previous close
29.98
0   0%

Share volume: 0
Last Updated: Tue 10 Nov 2020 06:00:00 AM CET
Medical Specialties: 0%

PREVIOUS CLOSE
CHG
CHG%

$29.98
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
28%
Profitability 0%
Dept financing 23%
Liquidity 57%
Performance 51%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$29.98
P/E Ratio 
N/A
DAY RANGE
$29.98 - $29.98
EPS 
-$0.85
52 WEEK RANGE
$23.14 - $30.74
52 WEEK CHANGE
$2.01
MARKET CAP 
3.895 B
YIELD 
N/A
SHARES OUTSTANDING 
129.935 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$128,213,491
AVERAGE 10 VOLUME 
$2,545,112
AVERAGE 30 VOLUME 
$1,497,294
Company detail
CEO: Robert J. Palmisano
Region: US
Website: http://www.wright.com
Employees: 3,030
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Medical Specialties
Sector: Health Technology

Wright Medical Group NV engages in the provision of medical device products. It operates through the following segments: U.S. Lower Extremities and Biologics; U.S. Upper Extremities; International Extremities and Biologics; and Corporate. The U.S. Lower Extremities and Biologics includes the sale of its lower extremities products, such as joint implants and bone fixation devices for the foot and ankle; and biologics products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. The U.S. Upper Extremities segment focuses on joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand; and products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries, and other ancillary products. The International Extremities and Biologics segment covers all lower and upper extremities products, as well as associated biologics products. The Corporate segment reflects general and administrative expenses not specifically associated with other segments. The company was founded by Frank O. Wright in 1950 and is headquartered in Amsterdam, the Netherlands.

Recent news